We are live on ! Find out more
BIOL

Biolase, Inc.

Delisted

BIOL was delisted on the 18th of June, 2024.

38 hedge funds and large institutions have $14.4M invested in Biolase, Inc. in 2021 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 5

80% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 5

23% more funds holding

Funds holding: 3138 (+7)

17% more capital invested

Capital invested by funds: $12.4M → $14.4M (+$2.06M)

Holders
38
Holders Change
+7
Holders Change %
+22.58%
% of All Funds
0.67%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
12
Increased
9
Reduced
5
Closed
5
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$4.46M
PCM
2
Perkins Capital Management
Minnesota
$2M +$8.16K +5 +0.4%
BlackRock
3
BlackRock
New York
$1.93M +$1.63K +1 +0.1%
Millennium Management
4
Millennium Management
New York
$1.01M +$1.01M +618 +5,150%
Renaissance Technologies
5
Renaissance Technologies
New York
$936K -$11.4K -7 -1%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$846K +$73.5K +45 +9%
GCP
7
GSA Capital Partners
United Kingdom
$802K +$820K +502 New
EIM
8
Essex Investment Management
Massachusetts
$511K +$522K +320 New
Marshall Wace
9
Marshall Wace
United Kingdom
$481K +$491K +301 New
State Street
10
State Street
Massachusetts
$267K -$80K -49 -23%
Two Sigma Advisers
11
Two Sigma Advisers
New York
$248K +$219K +134 +638%
Northern Trust
12
Northern Trust
Illinois
$179K +$3.27K +2 +2%
VF
13
Virtu Financial
New York
$133K -$6.53K -4 -5%
Two Sigma Investments
14
Two Sigma Investments
New York
$123K +$53.9K +33 +75%
DA
15
DCM Advisors
New York
$62K
Citadel Advisors
16
Citadel Advisors
Florida
$56K +$44.1K +27 +338%
Charles Schwab
17
Charles Schwab
California
$38K
Morgan Stanley
18
Morgan Stanley
New York
$36K +$11.4K +7 +44%
OCM
19
Orion Capital Management
California
$32K
Commonwealth Equity Services
20
Commonwealth Equity Services
Massachusetts
$31K +$32.6K +20 New
AI
21
Atom Investors
Texas
$30K +$31K +19 New
CS
22
Credit Suisse
Switzerland
$29K +$29.4K +18 New
Jane Street
23
Jane Street
New York
$26K +$26.1K +16 New
CG
24
CFO4Life Group
Texas
$21K
MA
25
MONECO Advisors
Connecticut
$19K

BIOL Hedge Fund Activity: Q3 2021 in Review

38 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Biolase, Inc. (BIOL) for Q3 2021, worth a combined $14.4M — up 17% from $12.4M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new BIOL positions and 5 closed out — a net gain of 7 holders — while 9 added to existing stakes and 5 trimmed.

The largest buyer was Millennium Management, adding an estimated $1.01M. The largest seller was Goldman Sachs, cutting an estimated $96.3K.

  • 38 institutional investors held Biolase, Inc. (BIOL) as of Q3 2021, up from 31 in Q2 2021.
  • Funds reported $14.4M of Biolase, Inc. stock for Q3 2021, up 17% quarter-over-quarter.
  • 12 funds opened new Biolase, Inc. positions in Q3 2021 and 5 closed out, a net change of +7 holders.
  • The largest Biolase, Inc. buyer in Q3 2021 was Millennium Management, an estimated $1.01M added.
  • The largest Biolase, Inc. seller in Q3 2021 was Goldman Sachs, an estimated $96.3K sold.

Based on aggregated 13F filings for Q3 2021.